The Hypomethylating Agent 5-Azacitidine Potentiates the Effect of RAS and Sp1 Inhibitors in Neuroblastoma Cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Neuroblastoma is a pediatric cancer with poor prognosis.
• DNA hypermethylation in neuroblastoma suggests potential for hypomethylating agents.
• Novel combination therapies are crucial for improving neuroblastoma treatment outcomes.

Purpose of the Study:

• To identify effective drug combinations for neuroblastoma treatment.
• To investigate the synergistic effects of 5-azacitidine with other agents.
• To elucidate the molecular mechanisms underlying combination therapy in neuroblastoma.

Main Methods:

• Transcriptomic analysis of neuroblastoma SH-SY5Y cells treated with 5-azacitidine.
• Experimental testing of drug combinations, including mithramycin A and lonafarnib.
• Analysis of signaling pathways (Sp1, RAS-MAPK), differentiation, and apoptosis using microscopy.

Main Results:

• 5-azacitidine combined with mithramycin A or lonafarnib demonstrated synergistic effects on SH-SY5Y cell death.
• These combinations target Sp1 and RAS-MAPK signaling pathways activated by 5-azacitidine.
• Combination therapy induced neuroblastoma cell differentiation and apoptosis.

Conclusions:

• Combination therapy with 5-azacitidine, mithramycin A, and lonafarnib shows promise for neuroblastoma treatment.
• Understanding the molecular mechanisms of cell death and adaptation can guide novel therapeutic development.
• Targeting Sp1 and RAS-MAPK pathways offers a potential strategy for overcoming neuroblastoma resistance.